There are different medications that are in various stages of clinical trials, so I can’t speak to those. But I think that with this new approach where we’re able to reduce amyloid and slow cognitive decline, there’s hope that we can continue maintaining this therapy and keeping amyloid from reaccumulating. Other proteins such as tau would be the next area where there is active investigation as to whether modulating tau levels could also change the rate of cognitive decline, either in conjunction with or sequential to reducing amyloid burden...
There are different medications that are in various stages of clinical trials, so I can’t speak to those. But I think that with this new approach where we’re able to reduce amyloid and slow cognitive decline, there’s hope that we can continue maintaining this therapy and keeping amyloid from reaccumulating. Other proteins such as tau would be the next area where there is active investigation as to whether modulating tau levels could also change the rate of cognitive decline, either in conjunction with or sequential to reducing amyloid burden. One is the fact that there are more neurology groups that are using anti-amyloid therapies. I saw a couple of abstracts presented where people are looking at serum as well as cerebrospinal fluid biomarkers and trying to see if those have predictive value in terms of determining who actually would best be suited to receive these therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
